3Harada K,Grossman W.Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts[J].J Clin Invest,1994,94:623.
4Banai S,Jaklitsch M T,Shou M,et al.Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs[J].Circulation,1994,89:2183.
1Jack H,Sonia S,Anand JL,et al.Guide to Anticoagulant therapy:Heparin:A statement for Healthcare professionals from the American heart association[J].Circulation,2001,103(24):2994-3018.
4Fareed J, Walenga Jm, Hoppensttudt DA, et al . Studies on the profibrnolytic actions of hepar in and its fractions semin [ J ]. Thromb Hemost, 1985,11:199 ～ 204.
5Vaiel EG, Brouty- Boye H, Toulemonde F, et al . Heparin and a low mole cular weight Fraction enhance thrombolysis and by this pathway exericise aprotective effect aginse thrombosis[ J]. Thromb - Res, 1983,30:219 ～ 243.
6Kakkar VV,stamatakis JD, Bentley PG, et al . Prophylaxis for pose - operative deep vein thrombosis[J]. JAMA, 1979,241: 39 ～ 43.
7Management of acute coronary syndromes:acute coronary syndromes without persistent ST segment elevation.Recommendations of the Task Force of the European Society of Cardiology.Eur Heart J 2000,21:1406-1432.
8ACC/AHA Guidejines for the management of patients with unstable angina and non-ST-segment elevation myocardial in farction:Executive Summary and Recommendations.Circulation 2000,102:1193-1209.
9Coben M,Demers C,Gurfinkel EP,et al.A Comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease.Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events Study Group.N Engl J Med 1997,337(7):447-452.
10Antman EM,McCabe CH,Gurfinkel EP,et al.Encoxaparin prevents death and cardiac ischaemic events in unstable angina/Non-Q-wave myocardial infarction.Results of the Thrombolysis in Myocardial Infarction(TIMI)11B trial.Circulation 1999,100:1593-1601.
